Patrizia R. Q.
- Country
- Italy
- Department
- Medicina Generale 2
Research Overview
- Phase 3 Randomized Double‑Blind Placebo‑Controlled Study of Efimosfermin Alfa in Adults with Biopsy‑Confirmed F2–F3 Metabolic Dysfunction‑Associated Steatohepatitis
- Phase 3 Randomized Double‑Blind Placebo‑Controlled Study of Efimosfermin Alfa Safety and Tolerability in Adults with F2‑F3 Metabolic Dysfunction‑Associated Steatohepatitis
- Phase III Randomized Double‑Blind Trial of Elecoglipron (AZD5004) on Cardiovascular Mortality and Hospitalization in Adults with HFpEF or HFmrEF on Background Dapagliflozin
Data & Insights
Has run more than one trial at 158 of 527 partner sites.
Specializations
Post-COVID Research
The investigator specializes in studying Post-Acute COVID Syndrome (PACS), focusing on therapeutic interventions for patients experiencing persistent respiratory symptoms after COVID-19 infection.
- Respiratory Health Management
- Post-COVID Complications
- Immune System Response
Their research explores innovative treatment approaches for managing long-term COVID-19 effects.
Immunological Studies
The investigator conducts research on immune system activation and its role in post-viral conditions, with particular attention to inflammatory response mechanisms.
- Inflammatory Markers
- Immune System Modulation
- Therapeutic Immunology
Their work examines immunological interventions in persistent post-viral symptoms.
Clinical Therapeutics
The investigator evaluates novel therapeutic approaches for treating persistent symptoms in post-viral conditions, focusing on safety and efficacy assessments.
- Treatment Efficacy
- Safety Monitoring
- Clinical Outcomes
Their research encompasses comprehensive evaluation of therapeutic interventions in complex medical conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.